Brookfield Asset Management and CDPQ Acquire Antylia Scientific from GTCR

AbbVie Acquires Aliada Therapeutics for $1.4 Billion

December 11, 2024

Biotechnology

AbbVie has completed the $1.4 billion acquisition of Aliada Therapeutics, a RA Capital- and JJDC-backed biotech developing ALIA-1758, an anti‑pyroglutamate amyloid beta antibody that uses a blood‑brain‑barrier crossing technology for Alzheimer's disease. The deal brings Aliada's CNS drug‑delivery platform and lead Phase 1 asset into AbbVie's neuroscience pipeline and represents an exit for RA Capital's Raven incubator and other early investors.

Avantor Acquires Masterflex Bioprocessing Business from Antylia Scientific

September 7, 2021

Medical Devices

Avantor, Inc. agreed to acquire the Masterflex bioprocessing business and related assets from Antylia Scientific for $2.9 billion in an all-cash transaction (net purchase price approximately $2.7 billion after tax structure). Headquartered in Vernon Hills, Illinois, Masterflex is a manufacturer of peristaltic pumps and single-use fluid transfer technologies with estimated 2022 revenues of ~$300 million; the deal bolsters Avantor's single-use and bioproduction capabilities and is expected to be accretive to adjusted EPS in year one.

AXA IM Alts and Swiss Life Asset Managers Acquire lyntia Networks

May 17, 2022

Telecommunications

AXA IM Alts (acting on behalf of clients) and Swiss Life Asset Managers have formed a joint venture to acquire Spanish wholesale fibre operator lyntia Networks from Antin Infrastructure Partners. Antin will retain and continue to operate the lyntia Access FTTH business; the deal (subject to regulatory approvals) adds a nationwide neutral lit and dark fibre network of over 43,000 km to the buyers' digital infrastructure portfolios.

Arcline Investment Management Acquires Polypeptide Therapeutic Solutions (PTS)

April 27, 2021

Biotechnology

Arcline Investment Management, a growth-oriented private equity firm, has acquired Polypeptide Therapeutic Solutions, S.L. (PTS) from Columbus Venture Partners. PTS is a Valencia-based GMP CDMO specializing in polyamino-acid (PAA) nanoparticle encapsulation and related drug-delivery services; Arcline plans to scale GMP production and expand the company's technology portfolio to support mRNA, gene/cell therapies, biologics and vaccines.

Adelis Equity Partners Acquires Majority Stake in Axentia Technologies

July 6, 2020

Transportation

Adelis Equity Partners has acquired slightly more than 50% of Axentia Technologies, becoming the company's majority owner while founders and management retain a significant stake. The investment will support Axentia's product development and international expansion of its low-power connected display systems and related software for the public transportation and rescue markets.

Adelis Equity Partners Becomes Majority Owner of Nordic BioSite Group

May 28, 2021

Healthcare Services

Adelis Equity Partners has acquired a majority stake in Nordic BioSite Group to accelerate the group's growth and pan‑European expansion of its life‑science research and diagnostics distribution platform. Tellacq Partners, together with the founders and management team, had built the group (including Nordic Biosite AB, Sanbio BV and Biomol GmbH); the parties did not disclose the purchase price.